



the **Hydroponics** company

www.thcl.com.au

ASX RELEASE (1st September)

PARTNERSHIP FOR NATIONAL ROLL OUT OF MEDICINAL CANNABIS FACILITATED PRESCRIBING AND DISPENSING

Key Points:

- ❖ The Hydroponics Company announces a partnership with Sinapse Pty Ltd for facilitated prescribed and dispensing of medicinal cannabis in Australia
- ❖ Single solution IT facilitated doctor prescribing, regulatory compliance, pharmacy wholesaler ordering and dispensing
- ❖ Sinapse works with leading global health and pharmaceutical companies on their business strategy, business optimisation and systems/program implementation. Their platform PharmaPrograms provides bespoke Health Care Professional - Patient Programs facilitated across Prescribers and Community Pharmacy. Since 2013 some 5000 prescribers and 4300 pharmacies have participated in PharmaPrograms initiatives
- ❖ The Medicinal Cannabis Medicines Portal (**MCMP**) to be launched in Q4 2017 together with Canndeo, and other foundation medicinal cannabis company participants, is anticipated to greatly streamline medicinal cannabis access for patients and support health professionals to be compliant with Commonwealth/State/Territory regulatory requirements
- ❖ Canndeo will use MCMP for facilitated prescribing and dispensing of its medicinal cannabis products in Australia.

The Hydroponics Company Limited (**ASX: THC**) is pleased to announce the first partnership with Sinapse Pty Ltd (**Sinapse**) as a key partner in its strategy to facilitate medicinal cannabis prescribing and dispensing in Australia.

Sinapse is an Australian company specialising in IT solutions for the resources, not for profit and pharmaceutical industries. Sinapse's portfolio of solutions includes PharmaPrograms, a sophisticated prescription authorisation and management software that has been deployed with 9 global pharmaceutical company partnerships.



The Hydroponics Company Limited
(ASX:THC) ACN: 614 508 039

Suite 305, Level 3, 35 Lime Street
Sydney, NSW, Australia. 2000.

PharmaPrograms provides bespoke Health Care Professional - Patient Programs facilitated across Prescribers and Community Pharmacy. Since 2013 some 5000 prescribers and 4300 pharmacies have participated in PharmaPrograms initiatives.

Sinapse / PharmaPrograms will launch the Medicinal Cannabis Medicines Portal (MCMP) (www.mcmp.com.au). The MCMP is a collaborative approach between Prescribers, Pharmacists and Sponsors to help patients get timely access to appropriate medicinal cannabis treatment in-line with all applicable National and State/Territory based laws and requirements. Sinapse, a health consultancy, has developed an IT based system to bring transparency to the process, products and price certainty for the prescribing and dispensing of medicinal cannabis in Australia. A launch of MCMP together with Candeo, and other foundation medicinal cannabis company participants, is anticipated for Q4 2017.

Candeo has been working closely with its partner Sinapse / PharmaPrograms to establish the MCMP which will facilitate the prescribing and dispensing of its medicinal cannabis products via the bulk sponsored import provisions under the Special Access Scheme (Category B) and Authorised Prescriber pathways. Candeo anticipates that the program will significantly streamline the process required for doctors to prescribe medicinal cannabis to Australian patients via the Special Access Scheme, a significant barrier to the wider adoption of medicinal cannabis in Australia.

THC Chairman Alan Beasley has commended the partnership, saying:

“The Hydroponics Company, via its wholly owned subsidiary Candeo, aims to provide workable solutions to the highly regulated medicinal cannabis market in Australia. I am very excited that Sinapse / PharmaPrograms together with Candeo will use its platform for the facilitated prescribing and dispensing of its medicinal cannabis products, and that this partnership will help Australians to access medicinal cannabis safely while dramatically decreasing administration time and ensure regulatory compliance for doctors and pharmacists”.

Candeo CEO Dr Andrew Beehag highlighted the importance of placing medicinal cannabis products on the Sinapse/ PharmaPrograms platform. He stated:

“Streamlining the prescribing and dispensing processes, and significantly reducing the administrative burden on doctors and pharmacists, is a key challenge for prescribing medicinal cannabis. I am very impressed with the innovation shown in Australia’s pharmacy sector, and that Sinapse has an ideal solution to the challenges of efficient delivery of medicinal cannabis to Australia’s patients”.

Sinapse Senior Health Strategist, PharmaPrograms Systems Architect and former National President of the Pharmacy Guild of Australia Kos Sclavos AM welcomed the support of The Hydroponics Company. He commented:

“We are pleased that THC acknowledges that prescribers and dispensers of medicinal cannabis require IT enabled support, and resources, to facilitate a streamlined process for patients to access medicine cannabis.”

Soula Skliros, Partner at Sinapse commented on the company’s IT platform:

“We have built a robust and proven IT platform which will support health professionals and partner portal companies to operate efficiently and effectively to support their patients.”

For further information, please contact:



Jarrod White
Company Secretary | Chief Financial Officer

The Hydroponics Company Limited

Suite 305, Level 3,
35 Lime Street
Sydney NSW 2000

P: +61 2 9251 7177



Michael Lovesey
Director Corporate Media Relations

MMR Corporate Services Pty Ltd

Level 2
131 Macquarie Street
Sydney, NSW 2000 Australia

P: +61 2 9251 7177

M: +61 449 607 636

E: michaell@mrrcorporate.com

About The Hydroponics Company

The Hydroponics Company (ASX:THC) is at the forefront of developing a leading, diversified worldwide cannabis business, focused on three core business units: Development and delivery of medicinal cannabis, manufacturing and distribution of hydroponics equipment, materials and nutrients, and large scale hydroponic greenhouse design and construction. With +17 years of Cannabis sativa breeding, variety selection and growth management, THC is actively developing plant breeding technology to target multiple markets for high purity cannabidiol (CBD), a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.